This study is looking at the feasibility of performing frailty assessments on patients with advanced hepatocellular cancer.
This study is primarily looking to see if it is feasible to assess frailty in patients with advanced hepatocellular cancer. It is also evaluating whether there may be any correlation between these assessments and toxicity of treatment and outcome. The assessments include: Frailty score, nutritional assessment, comorbidity score and quality of life. In addition sarcopenia will be assessed measuring muscle mass from imaging performed as part of routine clinical care. The assessments will be performed at baseline on entry into the study, at week 9 and week 18. There is the option for patients to also donate a blood samples for research purposes.
Study Type
OBSERVATIONAL
Enrollment
28
Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, United Kingdom
Percentage patients consenting for assessment out of number of patients approached
Number of patients consenting for the study as a percentage of the number of patients approached about the study
Time frame: baseline
Time taken to complete assessments
Time taken to completed assessments recorded by clinical trials officer
Time frame: Baseline, week 9 and week 18
Frailty as a predictor of grade 3/4 toxicity
Frailty score at baseline and during study time predict for outcome
Time frame: Baseline, week 9 and week 18
Muscle mass and timed get up and go as predictors of outcome
muscle mass as measured on routine CT scans and get up and go as measured in frailty score
Time frame: Baseline, week 9 and week 18
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.